In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246.
Human cytomegalovirus (HCMV) remains a serious threat for immunocompromised individuals, including transplant recipients and newborns. To date, all drugs licensed for the treatment of HCMV infection and disease target the viral DNA polymerase. Although these drugs are effective, several drawbacks are associated with their use, including toxicity and emergence of drug resistance. Hence, new and improved antivirals with novel molecular targets are urgently needed. Here we report on the antiviral properties of AIC246, a representative of a novel class of low-molecular-weight compounds that is currently undergoing clinical phase II studies. The anti-HCMV activity of AIC246 was evaluated in vitro and in vivo using various cell culture assays and an engineered mouse xenograft model. In addition, antiviral properties of the drug were characterized in comparison to the current gold standard ganciclovir. We demonstrate that AIC246 exhibits excellent in vitro inhibitory activity against HCMV laboratory strains and clinical isolates, retains activity against ganciclovir-resistant viruses, is well tolerated in different cell types (median selectivity index, 18,000), and exerts a potent in vivo efficacy in a mouse xenograft model. Moreover, we show that the antiviral block induced by AIC246 is reversible and the efficacy of the drug is not significantly affected by cell culture variations such as cell type or multiplicity of infection. Finally, initial mode-of-action analyses reveal that AIC246 targets a process in the viral replication cycle that occurs later than DNA synthesis. Thus, AIC246 acts via a mode of action that differs from that of polymerase inhibitors like ganciclovir.
Lischka
Peter
P
AiCuris GmbH & Co. KG, Friedrich Ebert Strasse 475, 42117 Wuppertal, Germany. peter.lischka@aicuris.com.
Hewlett
Guy
G
Wunberg
Tobias
T
Baumeister
Judith
J
Paulsen
Daniela
D
Goldner
Thomas
T
Ruebsamen-Schaeff
Helga
H
Zimmermann
Holger
H
D019342:Acetic Acid / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D002460:Cell Line; D002478:Cells, Cultured; D003587:Cytomegalovirus / Q000187:drug effects* / Q000502:physiology; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000821:virology; D003588:Cytopathogenic Effect, Viral; D020405:Dermis / Q000166:cytology; D004195:Disease Models, Animal; D005347:Fibroblasts / Q000821:virology; D006801:Humans; D008168:Lung / Q000166:cytology; D051379:Mice; D016513:Mice, SCID; D011799:Quinazolines / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D014183:Transplantation, Heterologous; D016896:Treatment Outcome; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D011799:Quinazolines; D019342:Acetic Acid